Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Young People and Illness Management and Recovery (IMR)

29 settembre 2022 aggiornato da: Anne-Lise Holmesland, University Hospital, Akershus

Young People's Experiences of Illness Management and Recovery (IMR) - an Explorative Study

The study is a combined clinical patient outcome study and a health-services research sub-study. Illness management and recovery (IMR) constitutes an evidence-based practice with 11 modules focusing on personal recovery developed for adults with severe mental health illnesses. IMR can be offered in groups or individually, once a week for 10-12 months.

Little is known about how young people experience the utility of IMR treatment groups in child and adolescent mental health outpatient clinics. The primary aim is to explore in-depth how the participants experience the utility of the IMR approach. The health research sub-study will provide new insights into the IMR implementation process in outpatient clinics for adolescents.

Panoramica dello studio

Stato

Terminato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

IMR has previously been implemented for adolescents in an inpatient unit in the hospital's catchment area. In order to offer the same treatment to all young patients, IMR treatment groups will be established in 4 out of 7 outpatient clinics in the hospital's catchment area. Participants belonging to the clinics in which no IMR treatment groups are being established will be invited to participate in IMR groups in clinics nearby.

The primary aim is to gain new insight into how young people experience the utility of IMR treatment groups conducted in outpatient practices and, if relevant, which changes could be made to adapt IMR more to young people. To explore how the participants experience the utility of IMR treatment groups, a qualitative focus-group study, consisting of a maximum of 5 focus-group interviews will be conducted. The participants in each IMR treatment group will be offered treatment once a week up to 10-12 months. To establish an IMR treatment group a minimum of 4 patients and a maximum of 8 participants must participate. Participants are mainly being included in the IMR treatment groups at the two primary admissions to each treatment group. Thus, some of the participants in the focus-groups may have participated in IMR groups for less than 10-12 months.

Secondary outcomes are related to fidelity to the model and the extent to which IMR treatment groups are implemented at an organizational level. The treatment groups will be led by trained IMR-therapists employed in inpatient units, together with therapists in training who are employed in outpatient clinics. Leaders and other clinicians in the outpatient clinics will contribute knowledge about the extent to which core components of IMR are being implemented, as well as information relating to quality improvement and individual adjustment. Two of the out-patient clinics in which no IMR group is being established will be included in the sub-study. The clinics will receive written feedback after each measurement time to support quality improvement.

The goal is to include up to 48 participants receiving IMR treatment in outpatient clinics. Up to 8 hospitalized participants will participate in a pilot focus-group interview. In the sub-study, a maximum of 16 IMR therapists, trained and in training, and up to 24 staff members will be invited to participate.

Tipo di studio

Osservativo

Iscrizione (Effettivo)

10

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Norvegia
      • Viken, Norvegia
        • Akershus Universitetssykehus

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 13 anni a 17 anni (Bambino)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Patients between 13-17 years of age suffering from or having symptoms of psychosis or bipolar disorders, and who participate in an IMR treatment group at one of the 4 (out of 7) outpatient clinics in the hospitals catchment area, and who are able to give informed consent. Up to 8 inpatients or previous inpatients between 13- 17 years of age suffering from various diagnoses will be invited to participate in a pilot focus-group interview. Trained clinicians and clinicians in training contribute to the implementation in the outpatient clinics together with clinic leaders and other clinicians.

Descrizione

Inclusion Criteria Patients:

Outpatient units:

  • Included in the IMR group in one of the outpatient clinics
  • Able to give informed consent

Inpatient unit (focus group):

  • 13-17 years of age
  • Current or previous patient
  • Able to understand and speak Norwegian
  • Able to give informed consent

Exclusion criteria (inpatient unit)

  • Younger than 13 years
  • Mental retardation
  • Manic phase

Inclusion Criteria: IMR therapists:

  • IMR therapist leading IMR treatment groups in one of the participating outpatient clinics
  • Trained or training in IMR
  • Employed at the Department for Child and Adolescent Mental Health Services at Akershus University Hospital.

Inclusion Criteria: Other staff members

• Employed at the Department for Child and Adolescent Mental Health Services at Akershus University Hospital.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
IMR patients
Patients from outpatient clinics receiving IMR from trained IMR therapists and IMR therapists in training.
Comportamentale: Illness management and recovery
Treatment given in groups, weekly for 10-12 months.
Altri nomi:
  • IMR
IMR therapists and other staff
Clinic leaders, IMR therapists and other staff participating in semi-structured individual or group interviews.
Altro: Semi-structured interviews
Semi-structured individual or group interviews conducted three times with staff on each participating outpatient clinic.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Focus-group interview aiming to explore the significance of the participant's own understanding of and knowledge about the disorder.
Lasso di tempo: End of treatment group, on average 11 months.
Focus-group interviews when the treatment group has come to an end aimed at exploring different perspectives on IMR treatment.
End of treatment group, on average 11 months.
Focus-group interview aiming to explore the impact of the IMR treatment on dealing with everyday life.
Lasso di tempo: End of treatment group, on average 11 months.
Focus-group interviews when the treatment group has come to an end aimed at exploring different perspectives on IMR treatment.
End of treatment group, on average 11 months.
Focus-group interview aiming to explore the importance of meeting other young people in the same situation.
Lasso di tempo: End of treatment group, on average 11 months.
Focus-group interviews when the treatment group has come to an end aimed at exploring different perspectives on IMR treatment.
End of treatment group, on average 11 months.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
The Illness Management and Recovery Scale (IMRS)
Lasso di tempo: Baseline (0 months), 6 and 12 months.
A 15-item scale that assesses illness self-management on a 5-point Likert scale where 5 indicates full self-management and 0 indicates no self-management. The scale measures consumer behavior relating to core components in the IMR program. The scale includes parallel clinician and consumer versions. Participants participating in IMR groups for less than 10-12 months will attend fewer measuring times.
Baseline (0 months), 6 and 12 months.
The Illness Management Fidelity Scale
Lasso di tempo: Baseline (0 months), 6 and 12 months.
Assesses the degree of fidelity with 13 items on a 5-point Likert scale where 5 indicates full implementation and 0 indicates no implementation. Filled in by researchers on the basis of a semistructured interview with staff members.
Baseline (0 months), 6 and 12 months.
General Organizational Index
Lasso di tempo: Baseline (0 months), 6 and 12 months.
A 12-item scale measuring organizational outcome of implementation, on a 5-point Likert scale where 5 indicates full implementation and 0 indicates no implementation. The scale is filled in by researchers on the basis of a semi-structured interview with staff members.
Baseline (0 months), 6 and 12 months.
Attendance registration
Lasso di tempo: Baseline (0 months), 3, 6, 9 and 12 months.
The number of sessions the patients are attending in the IMR treatment group.
Baseline (0 months), 3, 6, 9 and 12 months.

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Mapping the total number of patients identified receiving a psychosis-related diagnosis within the categories F 20-39 (ICD 10) for the years 2021-2023.
Lasso di tempo: End of treatment group, on average of 11 months.
The numbers will be displayed in the form of statistics obtained in the hospital. The numbers will be compared to what has been reported in the annual reports for the clinics from 2015 to 2020.
End of treatment group, on average of 11 months.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

University Hospital, Akershus

Investigatori

  • Investigatore principale: Anne-Lise Holmesland, PhD, University Hospital, Akershus

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

9 marzo 2021

Completamento primario (Effettivo)

30 giugno 2022

Completamento dello studio (Effettivo)

30 giugno 2022

Date di iscrizione allo studio

Primo inviato

14 febbraio 2021

Primo inviato che soddisfa i criteri di controllo qualità

26 febbraio 2021

Primo Inserito (Effettivo)

2 marzo 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

30 settembre 2022

Ultimo aggiornamento inviato che soddisfa i criteri QC

29 settembre 2022

Ultimo verificato

1 settembre 2022

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • 20/09657

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Illness management and recovery

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Uruguay

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

3
Sottoscrivi